OtherJun 1, 2026, 04:24 PM
BetterLife Pharma Inc. Files 20-F Amidst Significant Financial Uncertainty
AI Summary
BetterLife Pharma Inc. (BETRF) filed a 20-F report detailing its business, financial status, and risk factors. The company, incorporated in 2002 and renamed BetterLife Pharma in 2019, focuses on developing treatments for mental disorders and viral infections. As of January 31, 2026, BetterLife Pharma has an accumulated deficit of $120,091,493 and has not generated any revenue, raising substantial doubt about its ability to continue as a going concern. The report outlines its product candidates, BETR-001 (a non-hallucinogenic LSD derivative) and MM-001/MM-003 (interferon-based formulations), and highlights significant risks related to financing, regulatory approvals, and market acceptance.
Key Highlights
- Company incorporated in British Columbia on June 10, 2002, changed name to BetterLife Pharma Inc. on December 5, 2019.
- Focuses on developing compounds for mental disorders and interferon-based technologies for viral infections.
- Has an accumulated deficit of $120,091,493 as at January 31, 2026, with no revenue earned.
- Directors include Ahmad Doroudian, Doug Drysdale, Ralph Anthony Pullen, and Steven Sangha.
- Key management includes Doug Drysdale (Chairman), Ahmad Doroudian (CEO), Hooshmand Sheshbaradaran (COO), and Moira Ong (CFO).
- Auditors are MNP LLP.
- Selected financial data shows nil revenue for January 31, 2026, 2025, and 2024.
- Net loss for the year ended January 31, 2026, was $1,512,918.
Price Impact